Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Ruff

Showing results (151-160 of 224) with videos related to

Pageof 23
Sort By:
Circulation. Cardiovascular Quality and Outcomes|June 3, 2024
Application of the Win Ratio Method in the ENGAGE AF-TIMI 48 Trial Comparing Edoxaban With Warfarin in Patients With Atrial FibrillationBrian A Bergmark, Jeong-Gun Park, Rose A Hamershock, et al.
European Heart Journal|December 5, 2013
Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48Deepak K Gupta, Amil M Shah, Robert P Giugliano, et al.
JAMA Cardiology|January 19, 2017
The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation: A ReviewPaul L Hess, Jeff S Healey, Christopher B Granger, et al.
Circulation|February 15, 2021
Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 TrialThomas A Zelniker, Maddalena Ardissino, Felicita Andreotti, et al.
Lancet (London, England)|March 15, 2015
Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trialJessica L Mega, Joseph R Walker, Christian T Ruff, et al.
Stroke|July 9, 2016
Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)Natalia S Rost, Robert P Giugliano, Christian T Ruff, et al.
Journal of the American College of Cardiology|July 13, 2019
Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver DiseaseArman Qamar, Elliott M Antman, Christian T Ruff, et al.
Journal of the American Heart Association|August 27, 2024
Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient-Level Meta-Analysis From COMBINE AFLinda S Johnson, Alexander P Benz, Ashkan Shoamanesh, et al.
Circulation|January 30, 2026
Systemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-analysis of 71 683 Participants Randomized to NOAC Versus WarfarinSamer Al Said, Eugene Braunwald, Michael G Palazzolo, et al.
Journal of the American College of Cardiology|July 26, 2014
Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trialWillibald Hochholzer, Christian T Ruff, Robert A Mesa, et al.
Pageof 23

Showing results (151-160 of 224) with videos related to

Sort By:
Pageof 23
Circulation. Cardiovascular Quality and Outcomes|June 3, 2024
Application of the Win Ratio Method in the ENGAGE AF-TIMI 48 Trial Comparing Edoxaban With Warfarin in Patients With Atrial FibrillationBrian A Bergmark, Jeong-Gun Park, Rose A Hamershock, et al.
European Heart Journal|December 5, 2013
Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48Deepak K Gupta, Amil M Shah, Robert P Giugliano, et al.
JAMA Cardiology|January 19, 2017
The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation: A ReviewPaul L Hess, Jeff S Healey, Christopher B Granger, et al.
Circulation|February 15, 2021
Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 TrialThomas A Zelniker, Maddalena Ardissino, Felicita Andreotti, et al.
Lancet (London, England)|March 15, 2015
Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trialJessica L Mega, Joseph R Walker, Christian T Ruff, et al.
Stroke|July 9, 2016
Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)Natalia S Rost, Robert P Giugliano, Christian T Ruff, et al.
Journal of the American College of Cardiology|July 13, 2019
Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver DiseaseArman Qamar, Elliott M Antman, Christian T Ruff, et al.
Journal of the American Heart Association|August 27, 2024
Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient-Level Meta-Analysis From COMBINE AFLinda S Johnson, Alexander P Benz, Ashkan Shoamanesh, et al.
Circulation|January 30, 2026
Systemic Embolic Events in Atrial Fibrillation: An Individual Patient Data Meta-analysis of 71 683 Participants Randomized to NOAC Versus WarfarinSamer Al Said, Eugene Braunwald, Michael G Palazzolo, et al.
Journal of the American College of Cardiology|July 26, 2014
Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trialWillibald Hochholzer, Christian T Ruff, Robert A Mesa, et al.
Pageof 23